Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting ...

Boston, USA-based biotech Bambusa Therapeutics, which is developing bispecific antibodies for immunological and inflammatory ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell ...

As the pharmaceutical industry pivots towards bispecific antibodies, Ocean Biomedical's advancements position it favorably amid a surge of investment in this area, potentially paving the way for ...